Cigarette smoking is the primary cause of numerous preventable diseases; as such, the goals of smoking cessation are both to reduce health risks and to improve the quality of life. Currently, the first-line smoking cessation therapies include nicotine replacement products and bupropion. The nicotinic receptor partial agonist varenicline has recently been approved by the FDA for smoking cessation. A newer product currently under development and seeking approval by the FDA are nicotine vaccines. Clonidine and nortriptyline have demonstrated some efficacy but side effects may limit their use to second-line therapeutic products. Other therapeutic drugs that are under development include rimonabant, mecamylamine, monoamine oxidase inhibitors, and dopamine receptor D3 antagonists. Inhibitors of nicotine metabolism are also promising candidates for smoking reduction and cessation. In conclusion, promising new therapeutic products are emerging and they will provide smokers additional options to assist in achieving smoking cessation.

中文翻译：

---

用于戒烟的非烟碱疗法。

吸烟是许多可预防疾病的主要原因。因此，戒烟的目标既是减少健康风险，又是改善生活质量。当前，一线戒烟疗法包括尼古丁替代产品和安非他酮。烟碱样受体部分激动剂伐尼克兰最近已被FDA批准用于戒烟。尼古丁疫苗是目前正在开发并正在寻求FDA批准的较新产品。可乐定和去甲替林已显示出某些功效，但副作用可能将它们的使用限制在二线治疗产品上。正在开发的其他治疗药物包括利莫那班，美加明，单胺氧化酶抑制剂和多巴胺受体D3拮抗剂。烟碱代谢抑制剂也是减少和戒烟的有希望的候选者。总之，有希望的新治疗产品正在出现，它们将为吸烟者提供更多选择，以帮助他们戒烟。